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Heterozygous copy-number variants and SNPs of CNTNAP2 and NRXN1, two distantly related members of the neurexin superfamily,
have been repeatedly associated with a wide spectrum of neuropsychiatric disorders, such as developmental language disorders, autism
spectrum disorders, epilepsy, and schizophrenia. We now identiﬁed homozygous and compound-heterozygous deletions andmutations
via molecular karyotyping and mutational screening in CNTNAP2 and NRXN1 in four patients with severe mental retardation (MR) and
variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with Pitt-Hopkins syndrome.
With a frequency of at least 1% in our cohort of 179 patients, recessive defects in CNTNAP2 appear to signiﬁcantly contribute to severe
MR. Whereas the established synaptic role of NRXN1 suggests that synaptic defects contribute to the associated neuropsychiatric disor-
ders and to severe MR as reported here, evidence for a synaptic role of the CNTNAP2-encoded protein CASPR2 has so far been lacking.
Using Drosophila as a model, we now show that, as known for ﬂy Nrx-I, the CASPR2 ortholog Nrx-IV might also localize to synapses.
Overexpression of either protein can reorganize synaptic morphology and induce increased density of active zones, the synaptic
domains of neurotransmitter release. Moreover, both Nrx-I and Nrx-IV determine the level of the presynaptic active-zone protein
bruchpilot, indicating a possible common molecular mechanism in Nrx-I and Nrx-IV mutant conditions. We therefore propose that
an analogous shared synaptic mechanism contributes to the similar clinical phenotypes resulting from defects in human NRXN1 and
CNTNAP2.Introduction
The etiology of severe mental retardation (MR) is heteroge-
neous, and, despite a signiﬁcant number of identiﬁed
disease genes,1 the majority of cases, especially nonsyn-
dromic cases, remain unsolved.2 Many of the currently
known MR-related genes are involved in neurogenesis
and neuronal migration, and awareness of the implication
of synaptic organization and plasticity in MR has only
recently begun to rise.3,4 In 2007, haploinsufﬁciency of
the basic helix-loop-helix (bHLH) transcription factor 4
(TCF4) was identiﬁed as causative for Pitt-Hopkins syn-
drome (PTHS [MIM 610954]), a severe MR disorder
with variable additional anomalies, such as breathing
anomalies, epilepsy, and facial dysmorphism including
a beaked nose and a wide mouth with a cupid’s-bow-
shaped upper lip.5,6 TCF4 belongs to the E-protein family
of bHLH transcription factors, which bind as homo- and
heterodimers to E-box consensus sequences in promoters
of target genes.7 Like other E-proteins, TCF4 shows a broad
expression pattern and a high expression in the CNS.8,9
After the identiﬁcation of the underlying gene in 2007,
approximately 50 patients have been reported,5,6,8–11
demonstrating the importance of a diagnostic test for theThe Americanincreased recognition and appreciation of a previously
clinically underdiagnosed condition. Because of a similar
severe degree of MR, commonly associated seizures, and
microcephaly, PTHS has evolved as an important differen-
tial diagnosis to the two most common syndromic disor-
ders in severe MR, Rett (MIM 312750) and Angelman
(MIM 105830) syndromes.11 Because only 12% of patients
referred to us with suspected PTHS showed mutations in
TCF4 (Zweier et al.11 and unpublished data), the clinically
relatively homogenous group of 179 TCF4-mutation-nega-
tive patients, including two sibling pairs, represented a suit-
able study cohort for searching for additional candidate
genes for overlapping disorders.
Through molecular karyotyping and mutational anal-
ysis, we indeed identiﬁed recessive defects in two genes,
CNTNAP2 and Neurexin I (NRXN1), in patients with a
very similar severe MR disorder and variable additional
symptoms, such as seizures and breathing anomalies,
resembling Pitt-Hopkins syndrome. In light of the shared
phenotype that characterizes our patients with recessive
CNTNAP2 and NRXN1 defects, and on the basis of the
theme of overlapping phenotypes being caused by genes
that are linked with each other in molecular networks,12
we further aimed to address the hypothesis of a common1Institute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany; 2Department of Human Genetics, Nijme-
gen Centre for Molecular Life Sciences, Donders Institute for Brain, Cognition and Behaviour & Radboud University Nijmegen Medical Centre, 6525 GA
Nijmegen, The Netherlands; 3Unita Operativa Medicina Molecolare, Azienda Ospedaliera Universitaria Senese, Policlinico S. Maria alle Scotte, 53100 Siena,
Italy; 4Department of Clinical Genetics, Odense University Hospital, 5000 Odense C, Denmark; 5Wessex Clinical Genetics Service, Princess Anne Hospital,
Southampton, SO16 5YA, UK; 6Department of Clinical Genetics, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands; 7Institute of Medical
Genetics, University of Zurich, 8603 Zurich-Schwerzenbach, Switzerland
*Correspondence: czweier@humgenet.uni-erlangen.de
DOI 10.1016/j.ajhg.2009.10.004. ª2009 by The American Society of Human Genetics. All rights reserved.Journal of Human Genetics 85, 655–666, November 13, 2009 655
molecular pathogenesis. We therefore utilized the fruit ﬂy
Drosophila melanogaster as a model and collected data that
point to a common synaptic link between these two genes.
Subjects and Methods
Patients
Our study group consisted of 179 patients, including two sibling
pairs, who were referred for TCF4 testing because of severe
MR and variable additional features reminiscent of the PTHS
spectrum, such as microcephaly, dysmorphic facial gestalt, or
breathing anomalies. TCF4 mutational testing revealed normal
results in all of these patients. Ethics approval for this study was
obtained from the ethics committee of the Medical Faculty,
University of Erlangen-Nuremberg, and informed consent was
obtained from parents or guardians of the patients.
Molecular Karyotyping
Molecular karyotyping was performed in 48 patients with the
Affymetrix 500 K SNPArray and in 12 patients with the Affymetrix
6.0 SNP Array, in accordance with the supplier’s instructions. In
the index patient of family 1, hybridization was performed with
an Affymetrix GeneChipMapping 500K SNP array, and the second
affected patient and both parents were analyzed with the Affyme-
trix GeneChip Mapping 250K Nsp SNP array. Copy-number data
were analyzed with the Nexus software (Biodiscovery) and the
Affymetrix Genotyping Console 3.0.2 software. Molecular karyo-
typing in patients 2 and 3 was performed with the Affymetrix
GeneChip Mapping 6.0 array platform, and copy-number data
were analyzed with the Affymetrix software Genotyping Console
3.0.2. The identiﬁed copy-number variants (CNVs) were sub-
mitted to the Decipher database (patient 1a, 250902; patient 2,
250903; patient 3, 250904).
Mutational Screening
DNA samples from 177 patients, derived from peripheral-blood
or lymphoblastoid cell lines, were screened for CNTNAP2
(NM_014141) and NRXN1 (NM004801) mutations by unidirec-
tional direct sequencing of the coding exons 1–24 of CNTNAP2
and the coding exons 2–22 of NRXN1, including intronic ﬂanking
regions (ABI BigDye Terminator Sequencing Kit v.3; Applied
Biosystems), with the use of an automated capillary sequencer
(ABI 3730; Applied Biosystems). Mutations were conﬁrmed with
an independent PCR and bidirectional sequencing. Primer pairs
can be found in Table S1, available online. For splice-site predic-
tion, the online tools NNSPLICE 0.9 and HSF V2.3 were used.
FISH and MLPA
Fluorescence in situ hybridization (FISH) analysis was performed
in family 1 with the directly Cy3-labeled bacterial artiﬁcial chro-
mosome (BAC) clone RP4-558L10 onmetaphase spreads, in accor-
dance with standard protocols.
Probes for all coding exons of CNTNAP2 were designed and
MLPA reaction was performed in accordance with the guidelines
of MRC-Holland. The deletion in patient 3 was conﬁrmed with
MLPA with the use of a probe within exon 2 and a control probe
within exon 12 of NRXN1. Probe sequences are listed in Table S2.
Analysis of Relationship
The relationship of individuals within family 1 was analyzed, with
a four-generation family with known relationships used as back-656 The American Journal of Human Genetics 85, 655–666, Novemground, with the Graphical Representation of Relationships (GRR)
software.13 For GRR, we selected, from Affymetrix 250K arrays,
10,000 randomly distributed autosomal SNPs with a minimal
minor allele frequency of 0.2 in Europeans. For each pair of indi-
viduals, GRR calculates over the 10,000 markers the identical-
by-state (IBS) mean and standard deviation. The graphical plot of
IBS mean versus IBS standard deviation facilitates distinguishing
between relationships such as parents and offspring, siblings, half
siblings, and cousins, as well as identical or unrelated individuals.
Additionally, SNP genotypes around CNTNAP2 were analyzed in
the family members.
Drosophila Genes and Lines
Drosophila orthologs of TCF4, NRXN1, and CASPR2 (daughterless
[CG5102], Nrx-1 [CG7050], and Nrx-IV [CG6827]) were identiﬁed
by the ENSEMBLE genome browser or by the reciprocal BLAST
best-hit approach. Two RNAi lines, to Nrx-IV and daughterless,
respectively, were obtained from the Vienna Drosophila Research
Center (VDRC) and gave consistent phenotypes. VDRC lines no.
9039 (Nrx-IV) and no. 51297 (daughterless) were utilized for
further analysis. RNA interference was induced with the UAS-
Gal4 system. The w1118 line (VDRC no. 60000) was used as
a control, representing the same genetic background as the RNAi
lines. Flies were raised at 28C for maximum efﬁciency of knock-
down. The Nrx-I overexpression line pUAST-Nrx-I was obtained
from Wei Xie from Nanjing, China. Gal4 driver lines and the
inducible Nrx-IV overexpression line P(EP)Nrx-IVEP604 were
obtained from the Bloomington stock center.
Quantitative Real-Time PCR
RNA extraction from 333 L3 larvae of each genotype was per-
formed with the RNeasy Lipid Tissue Kit (QIAGEN) in accordance
with the supplier’s protocols. cDNA synthesis was performed with
iScript (Biorad). Quantitative real-time PCR was performed with
the Power SYBR Green PCR Master Mix on a 7500 Fast Real-Time
PCR System (Applied Biosystems), and results were normalized
to the endogenous control actin. Primer sequences can be found
in Table S3.
Immunostaining and Data Acquisition
We harvested 10–18 hr embryos and ﬁxed themwith 3.7% PFA for
20–25 min. All primary antibodies—anti-elav (labels nuclei of all
neurons), antibody 22c10 (sensory nervous system), antibody
BP102 (axon tracts, central neuropile region), anti-fas II (motor-
and central pioneer axons), and antibody nc82 (anti-bruchpilot,
synaptic active zones) (all from the Developmental Studies
Hybridoma Bank [DHSB])—were used in a 1:100 dilution. Late
stage (16/17), nc-82-labeled embryos were assigned to one of three
phenotypic categories: strong peripheral staining, moderate stain-
ing, and weak or residual staining, respectively. We performed
statistical analysis of 69 wild-type (WT) embryos (w1118) and 73
Nrx-IV knockdown embryos from three independent experiments
with a chi-square test and a Fisher’s-exact test to obtain p values.
The images for peripheral synaptic staining were obtained with
a Zeiss Apotome.
Brains were dissected from L3 larvae and ﬁxed for 30 min in
3.7% PFA. Pictures of WT and mutant brains were acquired with
the use of the samemicroscope settings. Intensities of nc82 immu-
nostainings were measured with Image J within two ﬁelds at two
standardized positions in each CNS, one in the upper third and
one in the lower third of the ventral nerve cord. The average ofber 13, 2009
these two values was normalized to the average of controls for
comparison of results from independent experiments. A total of
45 w1118 brains from six independent experiments, 11 elav-Gal4::
Nrx-I brains from two independent experiments, 19 double-
elav-Gal4::Nrx-I brains from three independent experiments, 12
elav-Gal4::Nrx-IV brains from two independent experiments,
and 21 double-elav-Gal4::Nrx-IV brains from four independent
experiments were measured. p values were obtained with a Wil-
coxon test for two samples for comparison to the WT.
Type 1b neuromuscular junctions (NMJs) of muscle 4 were
analyzed after dissection of L3 larvae and ﬁxation in 3.7% PFA
for 30 min. Costaining was performed with nc82 and DLG (both
from DHSB) or HRP (Jackson Immuno Research) antibodies in
a dilution of 1:500. NMJ pictures were stacked in ImageJ and pro-
cessed in Adobe Photoshop. Numbers of active zones and
branches were manually counted in an animated stack, and total
synaptic area was determined by ImageJ. A total of 21 WT NMJs,
19 overexpression Nrx-I NMJs, and 20 overexpression Nrx-IV
NMJs from at least two independent experiments were counted.
For the evaluation of branches, 27 WT NMJs, 25 overexpression
Nrx-I NMJs, and 20 overexpression Nrx-IV NMJs from three exper-
iments were counted.We performed statistical evaluation with the
Wilcoxon test for two samples, comparing each of the genotypes
to the WT. The antibody against NrxIV was obtained from Chris-
tian Kla¨mbt, Mu¨nster, Germany.14 Secondary antibodies for all
stainings were either Alexa 568- or Alexa 488-labeled antibodies
against mouse or rabbit (Molecular Probes). All data were acquired
blind to the evaluated phenotype.
Results
Identiﬁcation of Recessive Deletions and Mutations
in CNTNAP2 and NRXN1
Molecular karyotyping led to the identiﬁcation of a homo-
zygous deletion of exons 2–9 within theCNTNAP2 gene on
chromosome 7q35-q36.1 in a sibling pair of European
origin (P1a and P1b), formerly published as possible
clinical cases of Pitt-Hopkins syndrome.15 This deletion
was conﬁrmed by FISH analysis (Figure S2) and MLPA
(data not shown) and is predicted to be in frame but result
in the loss of several functional domains (Figure 1A,
Figure 2A, and Figure S1). Consanguinity of the parents
had been denied,15 and no indication for consanguinity
was found by analysis of relationship with the use of the
information of 10.000 SNPs. However, when the SNPs
within and around CNTNAP2 were analyzed, they showed
homozygosity in both children, indicating an allele of
common ancestry. By subsequent mutational screening
of CNTNAP2 in a larger cohort of 177 additional TCF4-
mutation-negative patients, we identiﬁed a third patient
of European origin (P2) with compound heterozygosity
for the splice mutation IVS10-1G>T and a partial in-frame
deletion of exons 5–8, identiﬁed by molecular karyotyping
(Figure 1B and Figure 2A) and conﬁrmed with MLPA. The
splice-site mutation resulted in lack of recognition of the
splice acceptor site by two splice-site-prediction programs
and is therefore predicted to result in loss of exon 10,
leading to a frame shift, and the deletion is predicted to
result in the loss of two laminin G domains. The splice-The Americasite mutation was not found in 384 control chromosomes,
and no CNTNAP2 deletion was found in 667 molecularly
karyotyped control individuals. In both families, the
parents were heterozygous carriers of one of the respective
defects.
In another European patient of our cohort who had
a very similar phenotype (P3), we identiﬁed a heterozygous
180 kb deletion within the NRXN1 gene on chromosome
2p16.3, spanning exons 1–4, including the start codon.
This deletion was inherited from the healthy mother, but
no deletions affecting the coding region of NRXN1 were
found in 667 molecularly karyotyped healthy controls.
Subsequent sequencing of NRXN1 in this patient revealed
a stop mutation in exon 15 on the second allele, which
was inherited from the healthy father (Figure 1C and
Figure 2B). Both mutations are predicted to result in loss
of the so-called alpha-isoform of NRXN1, one of two
NRXN1 isoforms that are transcribed from alternative
promoters. The presumably remaining shorter beta-
isoform (Figures 2B and 2C) appears not to be sufﬁcient
to ensure normal function, which is in accordance with
ﬁndings in alpha-neurexin knockout mice.16 Mutational
screening of NRXN1 in our study cohort did not reveal
any additional defects.
Clinical Characterization
As far as data are available, birth measurements of all
patients (P1a, P1b, P2, and P3)were normal. Further growth
development was also normal, apart from short stature in
the siblings from family 1 and additional microcephaly
in one of them. All four patients with recessive defects in
CNTNAP2 orNRXN1 showed severeMRwith lack of speech
orwith speech limited to singlewords (P1b), whereasmotor
milestones were normal or only mildly delayed, with a
walking age of 2 years in P3. Episodes of hyperbreathing
occurred in all patients, and seizures with an age at onset
between 4 months and 30 months were observed in P1a,
P1b, and P2. Additional variable anomalies were cerebellar
hypoplasia, autistic behavior, and stereotypic movements.
Apart from a wide mouth with thick lips in P1a and P1b
and a wide mouth in P3, no speciﬁc facial dysmorphisms
were noted (Figure 1D). Parents of all patients were healthy,
and the deceased sister of the father of P3 was said to have
hadepilepsy andmildMR.P1a andP1bhavebeendescribed
indetail byOrrico et al.,15 andanoverviewof clinical details
of all patients is shown in Table 1. Lack of NRXN1 and
CNTNAP2 expression in blood or ﬁbroblasts (Bakkaloglu
et al.17 and data not shown) precluded functional studies
on human material.
Analysis of CNTNAP2 and NRXN1 Orthologs Nrx-IV
and Nrx-I in Drosophila
Although a synaptic role for NRXN1 is known, this has not
yet been established forCNTNAP2. However, the high simi-
larity of clinical phenotypes caused by defects in the two
genes suggested a potential common molecular contribu-
tion. To address this, aswell as a further possible connectionn Journal of Human Genetics 85, 655–666, November 13, 2009 657
Figure 1. Pedigrees and Results of Molecular Karyotyping
(A) Pedigree of family 1, with two affected children and homozygous deletion of CNTNAP2 affecting exons 2–9. Both parents are hetero-
zygous carriers of the deletion. Results are frommolecular karyotyping with Affymetrix 250K SNP arrays and analysis with the Genotyp-
ing Console 3.0.2 software (Affymetrix). The deletion-ﬂanking SNPs in the 500K array of P1a are SNP_A-1991616 (145,562,641 Mb;
UCSC Human Genome Browser version 18 [hg18]) and SNP_A-1991672 (146,730,410 Mb; hg18), with a maximal deletion size of
1,167,269 bp and a minimal size of 1,146,016 bp (Nexus software).
(B) Pedigree of P2, with one affected child. The patient harbors an in-frame 180 kb deletion affecting CNTNAP2 exons 5–8 and a splice-
site mutation in the splice donor site of exon 11. Results of molecular karyotyping data from the Affymetrix 6.0 SNP array were analyzed
with the Genotyping Console 3.0.2 software, showing a deletion from CN_1217185 (146,387,354 Mb; hg18) to SNP_A-4269862
(146,566,863 Mb; hg18). See Figure S1 for SNP copy-number proﬁles.658 The American Journal of Human Genetics 85, 655–666, November 13, 2009
with TCF4, we utilized Drosophila as a model organism. All
three genes, TCF4, NRXN1, and CNTNAP2, are highly
conserved in evolution and have orthologs in Drosophila.
We initially hypothesized that the TCF4 ortholog
daughterless might regulate Nrx-I and Nrx-IV as transcrip-
tional targets. Knockdown of daughterless to 60% of WT
levels by the use of two different ubiquitous driver lines
(promoter-Gal4 lines that regulate inducible RNAi alleles;
see Subjects and Methods) resulted in pupal lethality, con-
ﬁrming the importance of daughterless for ﬂy development
(C) Pedigree of P3, with a compound-heterozygous deletion of NRXN1 exons 1–4 and a stop mutation in exon 15. Results of molecular
karyotyping data from the Affymetrix 6.0 SNP array were analyzed with the Genotyping Console 3.0.2 (Affymetrix), showing a 113 kb
deletion between CN_864223 (51,001,003 Mb; hg18) and CN_864269 (51,113,677 Mb; hg18).
(D) Clinical pictures of P2, with a compound-heterozygous deletion and mutation in CNTNAP2 and of patient 3, with a compound-
heterozygous deletion and mutation in NRXN1. Apart from a wide mouth in patient 3, no speciﬁc dysmorphisms are noted.
Figure 2. Structure of CNTNAP2 and NRXN1
(A) Schematic drawing of the genomic structure of CNTNAP2 with color coding for domain-coding exons and localization of mutations
and deletions. Black bars represent deletions. Abbreviations are as follows: SP, signal peptide; DISC, discoidin-like domain; LamG, lam-
inin-G domain; EGF, epidermal growth factor-like domain; FIB, ﬁbrinogen-like domain; TM, transmembran region; PDZPB, PDZ-
domain-binding site ; F1, family 1; P2, patient 2; Amish, homozygous mutation in the Amish population, published by Strauss et al.36
(B) Schematic drawing of the genomic structure of a-NRXN1 and b-NRXN1 with color coding for domain-coding exons and localization
of the mutation and deletion in patient 3, the deletion being represented by a black bar. Abbreviations are as follows: SP, signal peptide;
LamG, laminin-G domain; EGF, epidermal growth factor-like domain; TM, transmembrane region; PDZPB, PDZ-domain-binding site.
(C) Schematic drawing of the domain structure of neurexins, CASPR2, and CASPR in humans and Drosophila. In contrast to CASPR,
CASPR2 contains a PDZ-domain-binding site but lacks a PGY repeat region, rich in proline, glycine, and tyrosine residues. Both neurexin
I and CASPR2/Nrx-IV contain PDZ-domain-binding sites at their intracellular C terminus but differ in the presence of discoidin-like and
ﬁbrinogen-like domains and in the order of laminin-G domains.The American Journal of Human Genetics 85, 655–666, November 13, 2009 659
Table 1. Phenotype in Patients with CNTNAP2 and NRXN1 Mutations
Siblings
Patients P1a P1b P2 Amish36 (N ¼ 9) P3
Mutations CNTNAP2 deletion of
exons 2–9, homozygous
CNTNAP2 deletion of
exons 2–9, homozygous
CNTNAP2 deletion of
exons 5–8 þ IVS10-1G>T
CNTNAP2 c.3709delG,
homozygous
NRXN1 deletion of
exons 1–4 þ p.S979X
Age 20 yrs 15 yrs 11 yrs 1–10 yrs 18 yrs
Sex f m f not reported f
Parents healthy healthy healthy not reported healthy
Birth weight
Length
OFC
3700 g
51 cm
34.5 cm
not known 3700 g
at term
not reported 3450 g
normal
Height <P3 <P3 normal P4–P57 P50–P75
Weight P10 P5–P10 P50 not reported P50–P75
OFC <P3 P75 P75 P18–P99 P25
MR severe severe severe all severe
Age of walking normal normal not known 16–30 mo 2 yrs
Speech none single words none yes, but regression none
Age of seizure
onset
22 mo 25–30 mo 4–8 mo 14–20 mo none
MRI results cerebellar hypoplasia normal not known dysplasia in 43% normal
Hyperbreathing yes yes yes not reported yes
Stereotypies none not noted tooth grind., rep.
hand movements
yes
Autistic behaviour not noted not noted yes 67% yes
Developmental
regression
not noted not noted considered normal
until 8 months
yes, with onset
of seizures
normal the
ﬁrst years
Constipation not noted not noted no not reported yes
Decreased deep
tendon reﬂexes
not known not known not known 89% UE: decreased
LE: normal
Other broad mouth,
thick lips
broad mouth,
thick lips
dry skin broad mouth,
strabismus,
protruding tongue,
excessive drooling,
abnormal sleep-wake
cycles,
hypermotoric behavior
Normal testinga FRAXA, UBE3A,
MECP2, TCF4
FRAXA,UBE3A,
MECP2
UBE3A, CDKL5,
MECP2, TCF4
array CGH:b UBE3A,
MECP2, ZEB2, TCF4
Patients P1a and P1b are siblings from family 1, clinically described by Orrico et al.;15 Abbreviations are as follows: f, female; m, male; hom, homozygous; het,
heterozygous; MR, mental retardation; OFC, occipito-frontal circumference; rep. hand movements, repetitive hand movements; tooth grind., tooth grinding; UE,
upper extremities; LE, lower extremities.
a Previous genetic testing with reported normal results.
b Array-based comparative-genome hybridization via an Agilent 244K oligonucleotide array (Agilent).and viability.18 However, expression of Nrx-I and Nrx-IV in
L3 larvae of these genotypes was not signiﬁcantly changed
(Figure S3).
Drosophila Nrx-IV and Nrx-1 Both Determine
the Level of the Synaptic Protein Bruchpilot
Knockdown of Nrx-IV, either ubiquitously with the use of
actin-Gal4 drivers or speciﬁcally in neurons with the use of
an elav-Gal4 driver, resulted in late embryonic lethality,
with animals completing embryogenesis but failing to660 The American Journal of Human Genetics 85, 655–666, Novemhatch. Together with an only recently reported expression
of Nrx-IV in neurons,14,19 this suggests a crucial role in this
cell type. To evaluate the cause for lethality upon neuronal
knockdown, we performed immunostainings on embryos
with a series of neuronal markers, labeling all neuronal
nuclei, the sensory nervous system, main central axon
tracts, and motor- and central pioneer axons, respectively.
None of these showed abnormal position or morphology
(Figure S4 and data not shown). However, we noted an
overall diminished staining intensity of the presynapticber 13, 2009
Figure 3. The Presynaptic Protein Bruchpilot Is Misregulated in Nrx-IV Knockdown Embryos and Larval Brains with Neuronal Over-
expression of Nrx-I and Nrx-IV
(A and B) For quantitative evaluation, embryos have been assigned to one of three categories of bruchpilot (nc82) intensities: strong,
moderate, and weak peripheral staining. (A) Images of strong and moderate central (ventral nerve cord, left panel) and peripheral
(middle panel) presynaptic bruchpilot staining, representing the major fraction in WT and Nrx-IV knockdown embryos, respectively
(UAS-Nrx-IVRNAi/þ; elav-Gal4/þ [Elav::RNAi Nrx-IV]). Note that peripheral and central synaptic staining of bruchpilot in the Nrx-IV
knockdown embryos is diminished. Costaining with an anti-HRP marker, staining neuronal membranes, ensured the same focal plane
in mutant and WT embryos. Arrowheads point to a speciﬁc identiﬁable synapse (the muscle 6/7 synapse). Bruchpilot staining of this
synapse is depicted in insets in the middle panels. (B) Quantitative analysis of nc82 (anti-bruchpilot, synaptic active zones) labeling.
Diagram shows mean with standard deviation.
(C) Representative pictures of bruchpilot staining in brains with neuronal overexpression of Nrx-I or Nrx-IV as a result of the following
genotypes:WT, UAS-Nrx-I/ elav-Gal4; elav-Gal4/þ (dbElav:: Nrx-I) and elav-Gal4/þ; UAS-Nrx-IV/ elav-Gal4 (dbElav:: Nrx-IV). Bruchpilot
immunoreactivity is increased in both mutant conditions.
(D) Quantitative assessment of bruchpilot immunoreactivity in brains of genotypes shown in (C). The diagram shows the mean of
normalized intensity with the standard error of the mean. p values in (B) and (D) are related to the WT, respectively. Single asterisk,
p < 0.05; double asterisk, p < 0.01; triple asterisk, p < 0.0001.protein bruchpilot (nc82) in Nrx-IV knockdown embryos
(Figure 3A). Quantiﬁcation revealed that the fraction of
embryos with weak or residual staining on peripheral
motor synapses was signiﬁcantly increased to 33% in
Nrx-IV knockdown embryos, compared to 9% in WT
embryos, whereas the fraction of strongly stained embryos
was decreased to 25% in Nrx-IV knockdown embryos,
compared to 55% in the WT (Figure 3B).
Interestingly, bruchpilot is known to colocalize with
Nrx-I at presynaptic active zones, the domains of neuro-
transmitter release,20 and reduced levels of bruchpilot
immunoreactivity have been reported in larval brains of
Nrx-I mutants.21 We studied bruchpilot levels afterThe Americanneuronal overexpression of either Nrx-I or Nrx-IV and
found a signiﬁcant dosage-dependent increase of bruchpi-
lot-staining intensity in larval brains. Upon overexpres-
sion with one copy of a panneuronal elav-Gal4 driver,
bruchpilot intensity was increased 1.2- and 1.3-fold, and
introduction of a second copy (dbElav) resulted in a 1.6-
and 1.8-fold increase (Figures 3C and 3D).
Drosophila Nrx-IV Is Present at Synapses
and Can, Like Nrx-I, Reorganize Them
For further analyses at the subsynaptic level, we utilized
Drosophila larval NMJs, giant synapses that share a series
of features with central excitatory synapses in theJournal of Human Genetics 85, 655–666, November 13, 2009 661
Figure 4. Nrx-IV Localizes to Synapses and Its Overexpression Reorganizes Synapse Architecture
(A) Presence of endogenous Nrx-IV at type 1b neuromuscular junctions (NMJs) of muscle 4, overlapping with active zones stained with
nc82. White arrowheads point to Nrx-IV, labeling overlapping active zones.
(B) Synaptic terminal with increased bouton number and increased number of synaptic branches upon Nrx-I or Nrx-IV overexpression,
stained with an anti-HRP marker and the nc82 antibody. The enlarged section depicts the increased density of active zones.
(C) Increased bouton number per mm2 NMJ area in UAS-Nrx-I/ elav-Gal4; elav-Gal4/þ (dbElav:: Nrx-I) and elav-Gal4/þ; UAS-Nrx-IV/
elav-Gal4 (dbElav:: Nrx-IV) versus control w1118 animals (contr. 1) and dbElav control animals (contr. 2).
(D) Quantitative analysis of increased active-zone density (number per mm2 NMJ area) in neuronal Nrx-I and Nrx-IV overexpression.
(E) Increased number of synaptic branches in Nrx-I and Nrx-IV overexpression. Error bars indicate standard error of the mean. p values
are related to the WT (control 1). Single asterisk, p < 0.008; double asterisk, p < 0.0003; triple asterisk, p < 0.0001.mammalian brain and represent an established model for
the study of synaptic development and plasticity.22 Stain-
ing of these synapses with a recently characterized speciﬁc
antibody14 for Nrx-IV detected the presence of Nrx-IV at
synaptic terminals. Nrx-IV localizes in a pattern of subsy-
naptic foci that overlap active zones (Figure 4A), resem-
bling the pattern previously reported for Nrx-I.20
Previous studies in Nrx-I null mutants revealed a
decreased number of synaptic boutons in NMJs, whereas
overexpression of Nrx-I resulted in an increased bouton
number.20 Our results, measuring total synaptic area in
Nrx-I-overexpression animals, show that this goes along
with a morphological reorganization into smaller boutons,
as illustrated by an increased number of boutons per mm2
NMJ area (Figures 4B and 4C). Strikingly, overexpression662 The American Journal of Human Genetics 85, 655–666, Novembof Nrx-IV is capable of inducing the same morphological
changes (Figures 4B and 4C). Furthermore, overexpression
of either Nrx-I or Nrx-IV resulted in a highly signiﬁcant
increase in density of active zones (Figures 4B and 4D)
and in a signiﬁcant increase in branching of synaptic
terminals (Figures 4B and 4E).
Discussion
Recessive Defects in CNTNAP2 and NRXN1 Cause
Severe MR
We report here on homozygous and compound-heterozy-
gous deletions and mutations in NRXN1 and CNTNAP2
that cause severe MR with additional features such aser 13, 2009
epilepsy, autistic behavior, and breathing anomalies.
Heterozygous CNVs or SNPs in both genes have recently
been extensively reported in association with autism-spec-
trum disorder (ASD) (AUTS15, [MIM 612100]), epilepsy, or
schizophrenia.17,23–33 Additionally, for CNTNAP2, an asso-
ciation with Gilles de la Tourette syndrome and obsessive
compulsive disorder34 was reported to be due to a disrup-
tion of the gene but was not conﬁrmed in another
family.35 Furthermore, a homozygous stop mutation in
CNTNAP2 in Old Order Amish children was implicated
in a distinct disorder, CDFE syndrome (MIM 610042),
which is characterized by cortical dysplasia and early
onset, intractable focal epilepsy leading to language
regression, and behavioral and mental deterioration;36
as well as periventricular leukomalacia and hepatomegaly
in an additional patient.37 Histological examination of
temporal-lobe specimens of these patients showed evi-
dence of abnormal neuronal migration and structure, as
well as a possibly altered expression of Kv1.1 and Nav1.2
channels, therefore providing a possible explanation for
the cortical dysplasia and epilepsy phenotypes.36
Taken together, published data and the present study
indicate that heterozygous defects or variants in both
NRXN1 and CNTNAP2 can represent susceptibility factors
for variable cognitive, neurological, and psychiatric disor-
ders, whereas biallelic defects result in a fully penetrant,
severe neurodevelopmental disease such as that observed
in our patients, thus representing different ends of the clin-
ical spectrum caused by either monoallelic or biallelic
defects in these two genes. This is in accordance with a
report by Zahir et al.,38 who described a patient with a
heterozygous de novo NRXN1 deletion affecting the same
exons as those in our patient 3 but without detectable
mutation on the second allele. This heterozygous deletion
was associated with vertebral anomalies, behavioral prob-
lems, and only mild cognitive abnormalities. Of note, in
our families, none of the heterozygous parents had a history
of autism, epilepsy, or schizophrenia, and none of other
familymembers areknowntohave thesedisorders.However,
the deceased sister of the father of patient 3 was said to
have had epilepsy andmild MR.Whether or not this relates
to the mutation in the father’s family remains elusive.
A common feature in the Amish patients with a homozy-
gous stop mutation and in our patients with homozygous
deletions or compound-heterozygous deletion and muta-
tion in CNTNAP2 is the early onset of seizures. In contrast,
none of our patients showed regression of speech develop-
ment. Another difference is episodic hyperbreathing,
present in our patients but not reported in the Amish
patients. Cortical dysplasia, occurring in some of the
Amish patients, was not observed in our patients; however,
the number of patients examined with MRI is too low to
allow any deﬁnite conclusions to be drawn. The pheno-
typic differences between our patients and the reported
Amish patients may be explained by the loss of C-terminal
transmembrane and cytoplasmic domains in the Amish
mutation36 and by the loss of N-terminal extracellularThe Americandomains in our patients (Figure 2 and Table 1). However,
clinical bias cannot be excluded.
Resemblance among the patients in this study who have
recessive defects in CNTNAP2 or NRXN1 is high, with the
exception of patient 3, who has NRXN1 defects but no
seizures. It might even be speculated that the epilepsy,
observed in patients with recessive CNTNAP2 defects but
not in our patient with the compound-heterozygous
NRXN1 defect, might be associated to the previously
observed neuronal-migration anomalies,36 whereas the
remaining common symptoms such as severe MR and
autistic behavior might be caused by overlapping synaptic
anomalies. All of the reported patients were originally
referred for TCF4 analysis as a result of phenotypic resem-
blance to Pitt-Hopkins syndrome with regard to facial
aspects, the severity of MR, and breathing anomalies.
Nevertheless, phenotypical differences were noticeable.
In contrast to patients with Pitt-Hopkins syndrome, who
present an equally severe delay or lack of both motor and
speech development, patients with CNTNAP2 or NRXN1
defects, also severely impaired in speech development,
present with normal or only mildly to moderately delayed
motor milestones. These ﬁndings are in line with the
previously reported speciﬁc involvement of CNTNAP2 in
language development.26
Because of the similar phenotypes caused by defects
in both NRXN1 and CNTNAP2 and the resemblance to
Pitt-Hopkins syndrome, caused by haploinsufﬁciency of
TCF4, we investigated an as-yet-unappreciated common
molecular basis contributing to these disorders, using the
fruitﬂy Drosophila as a model. The Drosophila TCF4 ortho-
log daughterless belongs to the achaete-scute complex,
which encodes members of the bHLH class of transcrip-
tional factors with a well-established proneural function.18
Our initial hypothesis, that daughterless might regulate
Nrx-I and Nrx-IV as transcriptional targets, could not
be conﬁrmed by our analysis of their expression levels
in the daughterless knockdown condition (Figure S3).
However, given that the data were obtained from knock-
down animals, not null animals, this excludes neither
transcriptional regulation that is undetectable by our assay
nor other nontranscriptional interactions.
CNTNAP2 and NRXN1 Drosophila Orthologs Nrx-IV
and Nrx-I Might Be Involved in a Common
Synaptic Mechanism
Our identiﬁcation of a fully penetrant and severe MR
phenotype due to recessive defects in NRXN1 is in agree-
ment with NRXN1’s important role in synaptic function,
as previously suggested on the basis of its heterozygous
alterations that are associated with neuropsychiatric
disorders and work with animal models.39 NRXN1 belongs
to the evolutionarily conserved family of neurexins,
presynaptic transmembrane proteins. Each of the three
vertebrate neurexins has two promoters, generating longer
alpha-neurexins and shorter beta-neurexins. In addition,
extensive alternative splicing occurs, generating a largeJournal of Human Genetics 85, 655–666, November 13, 2009 663
number of variants, which may mediate target recognition
and synaptic speciﬁcity.40 Alpha-neurexins also play a role
in neurotransmitter release by coupling Ca2þ channels to
synaptic-vesicle exocytosis.41 In contrast to the three
neurexins in mammals, there is only one Drosophila
neurexin, termed Nrx-I or DNRX.20,21 Previously, defects
in several genes involved in synaptic pathways and
complexes have been reported to be causative for or
associated with MR or ASD, among them neurexin interac-
tors. The extracellular region of neurexins binds to post-
synaptic neuroligins, a family of proteins associated with
autism and MR,42 which in turn interact with the postsyn-
aptic protein SHANK3, also associated with ASD.43 The
binding of neurexins to neuroligins connects pre- and
postsynaptic neurons and mediates signaling across the
synapse,39 and the NRXN-NLGN-SHANK pathway is
supposed to be crucial during synaptogenesis, given that
mutations within this pathway lead to abnormal synapto-
genesis and excess of inhibitory currents.44 The intracel-
lular domains of neurexins interact with the synaptic
vesicle protein synaptotagmin and with PDZ-domain
proteins such as CASK,20,40 in which X-linked recessive
mutations were only recently identiﬁed to be causative
for MR and brain malformations.45
In contrast, a synaptic role of CNTNAP2 has not yet been
established. CNTNAP2 encodes CASPR2, a protein related
to neurexins. However, on the basis of its additional
motifs, different domain organization,40 and phylogenetic
analyses,20 only a distant relationship was assumed.46
Caspr2 regulates neuron-glia contact in vertebrates and
has been shown to colocalize with Shaker-like Kþ chan-
nels in the juxtaparanodal areas of Ranvier nodes in
myelinated axons of both the central and peripheral ner-
vous system.47,48 Until recently, its ﬂy ortholog Nrx-IV
was reported to be almost exclusively expressed in glial
cells49 and to regulate glia-glia contact in insects via septate
junctions that are important for maintaining an intact
blood-brain barrier.46 A detected decrease in evoked neuro-
transmitter release and an occasional failure to form
synapses in Nrx-IV null mutants was interpreted as a con-
sequence secondary to glial dysfunction.49 However,
recently, a neuronal Nrx-IV isoformwas also identiﬁed.14,19
Despite the knowledge of neuronal expression of vertebrate
Caspr2,50 so far only a report on detection of the protein in
fractionated rat synaptic plasma membranes pointed to
a possible synaptic presence.17 Our ﬁndings now support
a synaptic localization of Nrx-IV (Figure 4).
Previous studies at Drosophila neuromuscular junctions
had reported a decreased number of synaptic boutons in
Nrx-I null mutants and an increase upon overexpression
of Nrx-I.20 Our observation that the latter goes in hand
with an increased active-zone density and the ﬁnding
that Nrx-IV overexpression is causing the very same
phenotypes (Figure 4) suggest a crucial and possibly
common role for both proteins in the morphological orga-
nization of synapses. Moreover, published data for Nrx-I
mutants21 and our analysis of Nrx-IV knockdown and664 The American Journal of Human Genetics 85, 655–666, Novemoverexpression conditions of Nrx-I and Nrx-IV suggest
an important role of both proteins in bidirectional regula-
tion of bruchpilot levels. Bruchpilot is a presynaptic
protein crucial for the structure of active zones, the
subsynaptic domains of neurotransmitter release, and is
present at most if not all synapses of Drosophila. It
shows high sequence and functional homology to the
vertebrate family of ELKS/CAST proteins,51 corresponding
to ERC1 and ERC2 in humans with similar reported
functions. The mechanism by which Nrx-I and Nrx-IV
determine bruchpilot levels remains the subject of future
study. Given that all three contain C-terminal PDZ-domain
binding sites, which are necessary for the formation of large
complexes with active-zone proteins,51 one reasonable
hypothesis is that the three proteins might assemble into
a synaptic complex or macromolecular network.
In conclusion, we have identiﬁed here autosomal-reces-
sive defects in CNTNAP2 and NRXN1 in patients with
severe MR and variable additional features overlapping
with Pitt-Hopkins syndrome. With a frequency of at least
1% in this cohort, mutations in CNTNAP2 in particular
appear to signiﬁcantly contribute to severe MR. Using
the fruitﬂy as a model organism, we observed that not
only Nrx-I but also Nrx-IV, previously unrecognized as
a synaptic protein in vertebrates and in Drosophila, is
present at synapses and regulates levels of the active-zone
protein bruchpilot. It is therefore tempting to hypothesize
that misregulation of the human bruchpilot ortholog
might underlie a common synaptic pathomechanism
contributing to the similar phenotypes observed in
patients with defects in CNTNAP2 and NRXN1.
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